Bridgefront Capital’s Biogen BIIB Stock Holding History

Bridgefront Capital’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-6,010	Closed	-$1.1M	–	524
2026 Q1	$1.1M	Buy	+6,010	New	+$1.11M	0.27%	111
2025 Q4	–	Sell	-1,962	Closed	-$275K	–	536
2025 Q3	$275K	Buy	+1,962	New	+$265K	0.08%	425
2025 Q2	–	Sell	-5,275	Closed	-$722K	–	616
2025 Q1	$722K	Buy	+5,275	New	+$754K	0.21%	158
2024 Q4	–	Sell	-3,243	Closed	-$629K	–	587
2024 Q3	$629K	Buy	+3,243	New	+$678K	0.24%	132
2023 Q3	–	Sell	-975	Closed	-$278K	–	403
2023 Q2	$278K	Buy	+975	New	+$290K	0.15%	276
2023 Q1	–	Sell	-1,445	Closed	-$400K	–	424
2022 Q4	$400K	Sell	1,445 -144	-9%	-$40.7K	0.28%	140
2022 Q3	$424K	Buy	+1,589	New	+$337K	0.43%	62

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bridgefront Capital's BIIB Position: Q2 2026 in Review

Bridgefront Capital sold out of Biogen (BIIB) in Q2 2026, closing a stake of 6,010 shares — an estimated $1.1M sold.

Bridgefront Capital first reported a position in BIIB in Q3 2022 and held it in 7 quarters. The position peaked at $1.1M in Q1 2026. 1,046 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Bridgefront Capital reported no remaining Biogen position as of Q2 2026 after selling out during the quarter.
Bridgefront Capital sold 6,010 Biogen shares in Q2 2026, an estimated $1.1M.
Bridgefront Capital first reported a position in Biogen in Q3 2022 and held it in 7 quarters.
Bridgefront Capital's Biogen position peaked at $1.1M in Q1 2026.
1,046 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Bridgefront Capital's 13F filing for Q2 2026, filed 14 Aug 2026.